DUBLIN, March 24, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the first patient implants in the TITAN 2 pivotal study that will evaluate ...
Medtronic is upping the ante in patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic's InterStim device, an implanted ...
Medtronic plc reported its tibial neuromodulation device was implanted in the first patient with overactive bladder as part of its Titan 2 pivotal study. The device stimulates the posterior tibial ...
New Investigational Device Aims to Expand Access to Therapy for Patients with Incontinence; Underscores Medtronic's Leadership as Only Company to Offer Neuromodulation Options for Incontinence DUBLIN, ...
After receiving an FDA approval last month in bladder and bowel incontinence for its neuromodulation device implanted in the lower back, Medtronic isn’t resting on its laurels. It has begun a clinical ...
Concept: Medtronic has developed implantable tibial neuromodulation (TNM) device that aims to offer a therapy designed to provide relief from symptoms of bladder incontinence. It received US Food and ...
Minze Health NV signed a three-year agreement with Medtronic plc to bring its Minze Diary Pod, an app-controlled automated urine collection device, to markets across the EMEA region. The partnership ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results